KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
about
Differential response to ablative ionizing radiation in genetically distinct non-small cell lung cancer cells.Pilot assessment of vascular endothelial growth factor receptors and trafficking pathways in recurrent and metastatic canine subcutaneous mast cell tumours.The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.VEGF as a potential target in lung cancer.
P2860
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
KDR Amplification Is Associate ...... t to the VEGFR TKI Vandetanib.
@ast
KDR Amplification Is Associate ...... t to the VEGFR TKI Vandetanib.
@en
type
label
KDR Amplification Is Associate ...... t to the VEGFR TKI Vandetanib.
@ast
KDR Amplification Is Associate ...... t to the VEGFR TKI Vandetanib.
@en
prefLabel
KDR Amplification Is Associate ...... t to the VEGFR TKI Vandetanib.
@ast
KDR Amplification Is Associate ...... t to the VEGFR TKI Vandetanib.
@en
P2093
P2860
P50
P1476
KDR Amplification Is Associate ...... t to the VEGFR TKI Vandetanib.
@en
P2093
Alan Webster
Andrew Koo
Bruce E Johnson
Jayanthi Gudikote
Lixia Diao
Monique B Nilsson
P2860
P304
P356
10.1158/1078-0432.CCR-15-1994
P407
P577
2015-11-17T00:00:00Z